# A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old

> **NCT05083585** · PHASE3 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 250 (actual)

## Conditions studied

- Respiratory Syncytial Virus Prevention

## Interventions

- **BIOLOGICAL:** Ad26.RSV.preF-based vaccine

## Key facts

- **NCT ID:** NCT05083585
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-08
- **Primary completion:** 2022-03-07
- **Final completion:** 2022-09-22
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05083585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05083585, "A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05083585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*